block
Colorectal to Pancreatic: Mainz Biomed Expands Reach in Early Cancer Detection
Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular diagnostics company specializing in early cancer detection, continues to gain recognition as a pioneering force in the field. With a strong performance in 2024 and expanding global partnerships, the company is making bold strides in transforming how cancer is diagnosed—starting with colorectal and pancreatic cancers. Last year marked...
block
block